ReviewMolecules (Basel, Switzerland)2017
Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases.
Review in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Biochemistry of Human Gut Microbiota: Related Diseases and Dietary Interactions.Molecules (Basel, Switzerland) · 2026Review
- Short-chain fatty acids as a novel intervention for high-fat diet-induced metabolic syndrome.Molecular and cellular biochemistry · 2025Article
- Increasing spatial working memory in mice with Akkermansia muciniphila.Communications biology · 2025Article
- Protective effect of serum carotenoids on mortality among metabolic syndrome patients: attenuated by lipid-lowering drugs.Nutrition journal · 2025Article
- Comparison of metagenomic analysis of fecal and gastrointestinal tract samples for identifying beneficial gut microorganisms.Frontiers in microbiology · 2025Article
- Assessing the impact of concurrent high-fructose and high-saturated fat diets on pediatric metabolic syndrome: A review.World journal of clinical pediatrics · 2024Review
- Lactiplantibacillus plantarum Regulated Intestinal Microbial Community and Cytokines to Inhibit Salmonella typhimurium Infection.Probiotics and antimicrobial proteins · 2023Article
- Identification of the Intestinal Microbes Associated with Locomotion.International journal of molecular sciences · 2023Article
- Comparative Analysis of Original and Replaced Gut Microbiomes within Same Individuals Identified the Intestinal Microbes Associated with Weight Gaining.Microorganisms · 2022Article
- A Novel Bacterium,Frontiers in microbiology · 2022Article
- Host Factors Affect the Gut Microbiome More Significantly than Diet Shift.Microorganisms · 2021Article
- The regional diversity of gut microbiome along the GI tract of male C57BL/6 mice.BMC microbiology · 2021Article
- Treatment of Hyperammonemia by Transplanting a Symbiotic Pair of Intestinal Microbes.Frontiers in cellular and infection microbiology · 2021Article
- Article
- Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome.International journal of molecular sciences · 2019Article
- Probiotics in human health and disease: from nutribiotics to pharmabiotics.Journal of microbiology (Seoul, Korea) · 2018Review
- Microbiota and metabolic diseases.Endocrine · 2018Review
- Gut Microbiota as a Missing Link Between Nutrients and Traits of Human.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a cluster of metabolic risk factors associated with central obesity, hyperglycemia, insulin resistance, dyslipidemia and high blood pressure. In recent decades, because of the remarkable increase in both prevalence and severity, MetS and its related diseases such as cardiovascular diseases (CVDs), obesity, hypertension and diabetes have become the main global burden and challenge in strategic management involving prevention and treatment. However, currently, the preventions and treatments based on pharmaceutical interventions do not provide a solution for MetS and its related diseases. Recently, gut microbiota showed clear evidence of preventing and/or treating MetS, shedding light on treating MetS and its related diseases through a completely different approach. In this review, we will interpret the effects of current pharmaceutical drugs used in preventing and treating MetS and its related diseases to understand remaining issues of those interventions. We will explore the possibility of developing gut microbiota as pharmabiotics in a completely new medication option for treating MetS and its related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.